DNA Damage and Repair Biomarkers of Immunotherapy Response.

DNA-damaging agents are widely used in clinical oncology and exploit deficiencies in tumor DNA repair. Given the expanding role of immune checkpoint blockade as a therapeutic strategy, the interaction of tumor DNA damage with the immune system has recently come into focus, and it is now clear that the tumor DNA repair landscape has an important role in driving response to immune checkpoint blockade. Here, we summarize the mechanisms by which DNA damage and genomic instability have been found to shape the antitumor immune response and describe clinical efforts to use DNA repair biomarkers to guide use of immune-directed therapies.Significance: Only a subset of patients respond to immune checkpoint blockade, and reliable predictive biomarkers of response are needed to guide therapy decisions. DNA repair deficiency is common among tumors, and emerging experimental and clinical evidence suggests that features of genomic instability are associated with response to immune-directed therapies. Cancer Discov; 7(7); 675-93. ©2017 AACR.

[1]  L. Alexandrov,et al.  Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas , 2017, The Journal of pathology.

[2]  C. Zahnow,et al.  Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.

[3]  P. A. Futreal,et al.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.

[4]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[5]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[6]  Catherine J. Wu,et al.  Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations , 2016, Gynecologic oncology reports.

[7]  K. Harrington,et al.  Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers , 2016 .

[8]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[9]  Christopher A. Miller,et al.  Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. , 2016, Cancer discovery.

[10]  S. Cairo,et al.  Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents , 2016, Oncotarget.

[11]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[12]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[13]  M. Salto‐Tellez,et al.  Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer , 2016, Journal of the National Cancer Institute.

[14]  M. Berger,et al.  Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Swisher,et al.  Biomarkers of Response and Resistance to DNA Repair Targeted Therapies , 2016, Clinical Cancer Research.

[16]  D. Merico,et al.  Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Zhijian J. Chen,et al.  Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.

[18]  S. Demaria,et al.  Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.

[19]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[20]  L. Garraway,et al.  Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. , 2016, JAMA oncology.

[21]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[22]  Randal J. Kaufman,et al.  The unfolded protein response in immunity and inflammation , 2016, Nature Reviews Immunology.

[23]  G. Freeman,et al.  Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. , 2016, JCI insight.

[24]  M. Kortylewski,et al.  STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. , 2016, Cell reports.

[25]  Jun S. Liu,et al.  Landscape of tumor-infiltrating T cell repertoire of human cancers , 2016, Nature Genetics.

[26]  Satoru Miyano,et al.  Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers , 2016, Nature.

[27]  K. Kelly,et al.  Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. , 2016 .

[28]  R. Kuick,et al.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer , 2016, Cell.

[29]  V. Hornung,et al.  Cre-dependent DNA recombination activates a STING-dependent innate immune response , 2016, Nucleic acids research.

[30]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[31]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[32]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[33]  J. D. Del Valle,et al.  Agonist-Mediated Activation of STING Induces Apoptosis in Malignant B Cells. , 2016, Cancer research.

[34]  Werner Meier,et al.  Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy , 2016, Cancer.

[35]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[36]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[37]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[38]  Lauren L. Ritterhouse,et al.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.

[39]  R. Weissleder,et al.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.

[40]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[41]  A. Snyder,et al.  Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.

[42]  Ian Tomlinson,et al.  A panoply of errors: polymerase proofreading domain mutations in cancer , 2016, Nature Reviews Cancer.

[43]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[44]  Adam D. Thomas,et al.  DNA damage and the balance between survival and death in cancer biology , 2015, Nature Reviews Cancer.

[45]  P. Jeggo,et al.  DNA repair, genome stability and cancer: a historical perspective , 2015, Nature Reviews Cancer.

[46]  Lauren L. Ritterhouse,et al.  Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.

[47]  F. Martinon,et al.  STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity , 2015, Proceedings of the National Academy of Sciences.

[48]  G. Barber.  STING: infection, inflammation and cancer , 2015, Nature Reviews Immunology.

[49]  L. Zitvogel,et al.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 , 2015, Science.

[50]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[51]  Di Chen,et al.  IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells , 2015, PloS one.

[52]  A. Rust,et al.  Adenoma development in familial adenomatous polyposis and MUTYH‐associated polyposis: somatic landscape and driver genes , 2015, The Journal of pathology.

[53]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[54]  Jorge Sabbaga,et al.  Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice , 2015, Oncotarget.

[55]  C. Drake,et al.  Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.

[56]  K. Cibulskis,et al.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes , 2015, Nature Biotechnology.

[57]  Michael S. Goldberg,et al.  The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.

[58]  T. Schumacher,et al.  Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. , 2015, Cancer cell.

[59]  P. Gimotty,et al.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer , 2015, Cancer Immunology Research.

[60]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[61]  S. Demaria,et al.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. , 2015, The Lancet. Oncology.

[62]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[63]  Michael S. Goldberg,et al.  Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model , 2015, Cancer Immunology Research.

[64]  A. Khanna.  DNA damage in cancer therapeutics: a boon or a curse? , 2015, Cancer research.

[65]  A. Ng,et al.  A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab , 2015, Oncoimmunology.

[66]  Joshy George,et al.  Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.

[67]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[68]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[69]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[70]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[71]  C. Scott,et al.  Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Klenerman,et al.  POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer , 2015, Clinical Cancer Research.

[73]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[74]  Mads Thomassen,et al.  Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. , 2015, JAMA.

[75]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[76]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[77]  A. Kröger,et al.  DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. , 2015, Immunity.

[78]  A. D’Andrea,et al.  A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. , 2015, Cancer research.

[79]  H. Ishwaran,et al.  Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.

[80]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[81]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[82]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[83]  Michael R Stratton,et al.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma , 2014, Nature Medicine.

[84]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[85]  E. Janssen,et al.  STING-Mediated DNA Sensing Promotes Antitumor and Autoimmune Responses to Dying Cells , 2014, The Journal of Immunology.

[86]  D. Lambrechts,et al.  Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.

[87]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[88]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[89]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[90]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[91]  G. Barber,et al.  Inflammation-driven carcinogenesis is mediated through STING , 2014, Nature Communications.

[92]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[93]  G. Garinis,et al.  DNA damage and innate immunity: links and trade-offs. , 2014, Trends in immunology.

[94]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[95]  P. Newell,et al.  TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models , 2014, Cancer Immunology Research.

[96]  K. Cibulskis,et al.  Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. , 2014, Blood.

[97]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[98]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[99]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[100]  F. Couch,et al.  Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer , 2014, Journal of the National Cancer Institute.

[101]  S. Ferrone,et al.  Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .

[102]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[103]  S. Demaria,et al.  An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer , 2013, Cancer Immunology Research.

[104]  X. Matías-Guiu,et al.  Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. , 2013, Critical reviews in oncology/hematology.

[105]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[106]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[107]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[108]  V. Hornung,et al.  cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING , 2013, Nature.

[109]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[110]  I. Dick,et al.  Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.

[111]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[112]  K. Ishii,et al.  DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking , 2013, Proceedings of the National Academy of Sciences.

[113]  J. Taube,et al.  Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.

[114]  S. Demaria,et al.  Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..

[115]  W. McBride,et al.  Regulatory T Cells in Radiotherapeutic Responses , 2012, Front. Oncol..

[116]  M. van den Broek,et al.  Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation , 2012, The Journal of Immunology.

[117]  M. Meyerson,et al.  Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential , 2012, Science.

[118]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[119]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[120]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  M. de Perrot,et al.  CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma , 2012, Molecular Cancer Therapeutics.

[122]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[123]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[124]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[125]  S. Pestka,et al.  Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells , 2012, PloS one.

[126]  Sohrab P Shah,et al.  BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma , 2012, Modern Pathology.

[127]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[128]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[129]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[130]  N. Reich,et al.  The DNA Damage Response Induces IFN , 2011, The Journal of Immunology.

[131]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[132]  Axel Hoos,et al.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.

[133]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[134]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[135]  A. Aboussekhra,et al.  Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule , 2010, Breast Cancer Research.

[136]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  J. Wolchok,et al.  Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. , 2010, Blood.

[138]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[139]  J. Hoeijmakers.  DNA damage, aging, and cancer. , 2009, The New England journal of medicine.

[140]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors , 2009, Nature Medicine.

[141]  G. Shurin,et al.  Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism1 , 2009, The Journal of Immunology.

[142]  Matt van de Rijn,et al.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.

[143]  V. Sondak,et al.  Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[144]  S. Xiong,et al.  Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. , 2008, Clinical immunology.

[145]  N. Kawashima,et al.  Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells1 , 2008, The Journal of Immunology.

[146]  S. Steinberg,et al.  High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma , 2008, Cancer.

[147]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[148]  R. Ward,et al.  The role of MYH and microsatellite instability in the development of sporadic colorectal cancer , 2006, British Journal of Cancer.

[149]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[150]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[151]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[152]  Roman K. Thomas,et al.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. , 2005, Blood.

[153]  J. Witjes,et al.  Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. , 2005, The Journal of urology.

[154]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[155]  T. Ørntoft,et al.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis , 2005, Nature.

[156]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[157]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[158]  J. Schlom,et al.  Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.

[159]  B. Quesnel,et al.  Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells , 2004, Leukemia.

[160]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[161]  N. Kawashima,et al.  Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. , 2004, International journal of radiation oncology, biology, physics.

[162]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[163]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[164]  C. N. Coleman,et al.  Irradiation of Tumor Cells Up-Regulates Fas and Enhances CTL Lytic Activity and CTL Adoptive Immunotherapy , 2003, The Journal of Immunology.

[165]  W. Symmans,et al.  Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[166]  T. Smyrk,et al.  Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.

[167]  R. Fisher,et al.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  Teruhiko Yoshida,et al.  Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. , 1999, Gastroenterology.

[169]  R. Dummer,et al.  Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  D. Hallahan,et al.  Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. , 1996, Cancer research.

[171]  D. Hallahan,et al.  Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[172]  J. Le Bourgeois,et al.  [Whole body irradiation]. , 1989, Pathologie-biologie.

[173]  S. Order.  The effects of therapeutic irradiation on lymphocytes and immunity , 1977, Cancer.

[174]  D. Kingsley.  An interesting case of possible abscopal effect in malignant melanoma. , 1975, The British journal of radiology.

[175]  Mole Rh.  Whole body irradiation; radiobiology or medicine? , 1953 .

[176]  S. Jackson,et al.  Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. , 2017, Cancer discovery.

[177]  A. D’Andrea,et al.  Repair Pathway Choices and Consequences at the Double-Strand Break. , 2016, Trends in cell biology.

[178]  K. Kinzler,et al.  The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.

[179]  J. Wolchok,et al.  Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.

[180]  T. Lynch,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[181]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[182]  A. Melcher,et al.  T-cell responses to survivin in cancer patients undergoing radiation therapy , 2008 .

[183]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.

[184]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[185]  J. Ward.  Nature of Lesions Formed by Ionizing Radiation , 1998 .